JPRN-jRCT1080222475未知1 期
An Open-Label, Multiple Ascending-Dose, Study to Evaluate the Pharmacokinetic Profile and D2 Occupancy of HP-3070 Patch in Subjects Diagnosed with Schizophrenia.
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •Subjects who meet the diagnostic criteria for schizophrenia or schizoaffective disorder according to the DSM-IV-TR for at least 1 year before screening.
排除标准
- •- Subjects who have an active DSM-IV-TR axis I diagnosis other than schizophrenia or schizoaffective disorder.
- •- Subjects who have a history of substance dependence within 6 months before screening or alcoholism.
研究者
相似试验
进行中（未招募）
1 期
Study to test the safety and tolerability of different doses (amounts) of sepofarsen (an RNA therapy) in children of age 3 to less than 8 years that have CEP290 mediated Leber Congenital Amaurosis 10 (LCA10) due to the c.2991+1655A>G mutatioeber Congenital Amaurosis 10 (LCA10) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 GeneMedDRA version: 20.0Level: PTClassification code 10070667Term: Leber's congenital amaurosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-000535-45-GBProQR Therapeutics10
进行中（未招募）
1 期
An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis ImperfectaEUCTR2017-004972-74-DEAmgen Inc.24
进行中（未招募）
1 期
An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis ImperfectaEUCTR2017-004972-74-HUAmgen Inc.16
进行中（未招募）
1 期
An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis ImperfectaEUCTR2017-004972-74-ATAmgen Inc.24
进行中（未招募）
1 期
An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis ImperfectaOsteogenesis imperfecta (OI) is a group of genetic skeletal disorderscharacterized by increased bone fragility, low bone mass , and increasedbone turnover contributing to osteoporosis, fractures, and otherconditions. OI is the most common form of primary osteoporosis inchildren with an estimated incidence of 1 per 25,000 live births.MedDRA version: 20.0Level: PTClassification code 10031243Term: Osteogenesis imperfectaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-004972-74-GRAmgen Inc.16